$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Medical drugs
Medical drugs
Medical drugs-Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Detailed compilation of indications, contraindications and precautions in the linezolid (Sivo) instructions
2026-02-01 22:25:32
Check Details
Ribociclib (Calilon) standard administration method, daily dosage schedule and dietary-related medication precautions
2026-02-01 22:25:32
Check Details
Are cemiplimab and cemiplimab the same drug and the reason for the difference in names?
2026-02-01 22:25:32
Check Details
The potential therapeutic effects and future value of Daprodustat in addition to conventional indications
2026-02-01 22:25:32
Check Details
Whether durvalumab (durvalumab) has been included in medical insurance and the reimbursement policy in 2025
2026-02-01 22:25:32
Check Details
How much does a complete one-year treatment with Zolbetuximab cost approximately and the key factors that affect the price
2026-02-01 22:25:32
Check Details
Whether EIKANCE 0.01% atropine sulfate eye drops can be used to control the progression of myopia and its efficacy evaluation
2026-02-01 22:25:32
Check Details
Aficamten-MYQORZO is a medicine that treats what
2026-02-01 22:25:32
Check Details
Manufacturer and brand information of mirikizumab
2026-02-01 22:25:32
Check Details
What is the best time to take Selumetinib/Coselyu?
2026-02-01 22:25:32
Check Details
Can lorlatinib/lorlatinib (Borina) be continued for a long time?
2026-02-01 22:25:32
Check Details
Is there a domestic version of Cabozantinib?
2026-02-01 22:25:32
Check Details
1
2
...
2427
2428
2429
2430
2431
2432
2433
...
2439
2440
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Neurokinin Receptor Antagonists: A Non-Hormonal Approach to Menopausal Hot Flashes and Sleep Disturbances
2
FDA Approves Tauklarify for Tau PET Imaging in Alzheimer's Disease Assessment
3
First CELMoD Drug Zenbexus Wins FDA Accelerated Approval for Multiple Myeloma
4
FDA Approves First mRNA Flu Vaccine mFLUSIVA
5
FDA Approves Orzeyful, the World's First Orexin Receptor Agonist for Narcolepsy Type 1, Ushering in a New Era of Root-Cause Therapy
6
FDA Approves Lytenava: First Ophthalmic Bevacizumab for Wet AMD
7
AbbVie’s TEPKINLY (epcoritamab) Plus R² Granted EU Approval for Relapsed/Refractory Follicular Lymphoma
8
Global Oncology Update: Breakthroughs in Advanced Cancer Survival and Novel Therapies
9
Phase 1 Study Progress of Ceralasertib in Combination with Durvalumab for Advanced NSCLC and HNSCC
10
Global Breakthroughs in Cancer Drugs and Advanced Treatment Technologies
11
ROS and Cancer: The Potential of Natural Antioxidants
12
SKYSCRAPER-02C Study: New Hope for Extensive-Stage Small Cell Lung Cancer Treatment